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Introduction

It has been generally accepted for over
twenty years that epinephrine stimulates platelet
aggregation without inducing shape change.
However, it has been recently reported that
discoid platelets are not recruited into ADP-or
epinephrine-stimulated
aggregates.
Previous work
in our laboratory has suggested that platelet
shape change is necessary for the binding of
fibrinogen to its surface receptor, which is a
prerequisite
for platelet aggregation.
These
studies seem to indicate that epinephrine-induced
platelet aggregation does involve shape change.
To investigate this possibility,
the extent of
shape change and fibrinogen binding in
suspensions of epinephrine- and ADP-activated and
control platelets was assessed by scanning
electron microscopy (SEM). Platelets were
incubated with 20 µMepinephrine, 20 µMADP, or
vehicle and labelled with 18 nm gold beads
conjugated to fibrinogen or to a monoclonal
antibody directed against the glycoprotein
!lb/Illa
complex which comprises the fibrinogen
receptor.
Results indicate that shape change
does occur in epinephrine-activated
platelets as
well as ADP-activated platelets.
Although GP
!lb/Illa was shown to be present on both discoid
and shape-changed, pseudopodial platelets,
a
significant
degree of fibrinogen binding did not
occur earlier than the pseudopodial stage in
either activated or control suspensions.
Platelet aggregation studies showed that the
majority of platelets involved in aggregates had
changed shape in both ADP-and epinephrinetreated platelet suspensions.
These studies
suggest that epinephrine- and ADP-induced
platelet aggregation occurs via the exposure of
fibrinogen receptors on shape-changed platelets.
KEYWORDS:Platelets,
receptor, Epinephrine,

form December

Platelet membrane glycoproteins regulate the
hemostatic activities
of platelets,
especially
those of adherence and aggregation.
The
fibrinogen receptor is of particular interest in
platelet studies because soluble fibrinogen has
been shown to be essential for platelet aggregation
(13,20,35,36,38,44,50,51),
and platelets
deficient in the glycoproteins which comprise the
fibrinogen receptor do not bind fibrinogen and do
not aggregate (6,11,34,45).
Following exposure to foreign surfaces or to
various activating agents, such as ADPor
thrombin, platelets undergo a well-characterized
activation sequence involving extensive shape
change, which is correlated with cytoskeletal
reorganization involving the polymerization of
actin into microfilaments
(2,4,5,8,19,26,53,56).
We have examined relative
numbers and distribution
of the fibrinogen
receptor on individual human platelets by
labelling the receptor with colloidal goldconjugated ligand or gold-conjugated antibodies,
followed by observation using scanning electron
microscopy (SEM). Thus, we have been able to
study, in individual platelets,
how relative
receptor numbers and receptor distribution relate
to cell activation state.
By means of
correlative high voltage transmission electron
microscopy (HVEM)of whole mounts, we have
observed the relationship of surface receptors to
the underlying cytoskeleton (4,23,24,33).
The glycoprotein llb/llla
complex (GP
llb/llla)
has been shown to serve as the platelet
receptor for fibrinogen, and also apparently for
other plasma proteins, such as fibronectin, which
contain the RGD(arg-gly-asp) amino acid sequence
(48). Our previous studies of the GP !lb/Illa
fibrinogen receptor have been carried out on
surface-activated
platelets,
and have shown that
the fibrinogen-gold labels (FGN/Au)will not bind
to platelets until significant shape change has
occurred (4,23,24,33).
This correlates well with
findings of classical radiolabelled ligand
binding studies, which indicate that fibrinogen
does not bind to an unactivated population of
platelets
(6,27,28,44,47).
However, the
fibrinogen receptor is present on the surface of
even unactivated platelets,
as is demonstrated by
the binding of a monoclonal antibody (3) which is
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optimal protein adsorption with 0.2 N K2co, as
measured by gel-filled
combination elecEro~e (No.
9115, Orion Research, Inc., Cambridge,MA).
Previous studies have shown the optimal pH to be
at or slightly above the pl of the protein
(3,16).

directed against the GP !lb/Illa complex and has
been shown to inhibit fibrinogen binding (12),
and also by the binding of small fragments of the
gammachain of fibrinogen (21). In addition, it
has been demonstrated that the advantage ligands
with small Stokes radii have in gaining access to
GP !lb/Illa
over larger ligands is decreased upon
activation (10).
The results of these previous studies
suggest that the shape change component of
platelet activation may be a prerequisite for
fibrinogen binding by acting to remove steric
hindrance caused by other platelet membrane
glycoproteins (33). Fibrinogen binding may also
be closely associated with cytoskeletal changes
coincident with shape change, which may direct a
reorientation
of the receptor in the plane of the
membrane. Since soluble fibrinogen is required
for platelet aggregation, it follows that shape
change may also be a prerequisite for platelet
aggregation due to a fibrinogen binding
requirement.
Arguments against the proposed relationship
between platelet shape change, fibrinogen
binding, and aggregation stem from results which
suggest that although platelets stimulated by
most aggregating agents, such as ADPor thrombin,
change shape prior to aggregation, platelets
appear to aggregate in response to epinephrine
without concurrent shape change (7,29,40,42).
However, Milton and Frojmovic have recently
examined the shapes of platelets in ADP-and
epinephrine-aggregated
stirred suspensions by the
use of phase contrast microscopy (30). They
observed a transient increase, followed by
disappearance, of free discoid platelets
throughout the course of aggregation, and an
accompanying increase in numbers of free
pseudopodial platelets.
They concluded that
shape-changed platelets were preferentially
recruited into early aggregates, whether the
aggregation was induced by ADPor epinephrine.
We presently report the use of SEMto
examine the shapes of individual platelets
activated by epinephrine and ADPto address the
question of epinephrine- and ADP-induced platelet
shape change. In addition, we have used
colloidal gold labelling to examine binding to
the fibrinogen receptor in epinephrine- and ADPactivated suspensions.
Materials

R.M. Albrecht

Conjugation of Protein to Colloidal Gold
The minimumconcentration of protein
necessary to stabilize the colloidal gold was
determined by adsorption isotherms (15,18). A
series of protein solutions of increasing
concentration were made up to 1.0 ml in deionized
distilled
water and added to 5.0 ml of the gold
solution at optimal pH. After 1 min. at room
temperature, 1.0 ml of 10%NaCl was added to the
protein-gold.
Inadequate stabilization
of the
colloid results in flocculation of the gold
granules, indicated by a color change from red to
blue.
Protein in 10-50% excess of the amount
required to stabilize 10 m1 of the gold granules
was brought to 1.0 ml with sterile filtered (0.22
µm Millipore, Type GS, Millipore Corporation,
Bedford, MA)deionized distilled water. Sterile
filtered (0.22 µm Millipore) colloidal gold was
then added to bring the volume to 10.0 ml and
mixed gently.
After 5 min. at room temperature,
0.5 ml of freshly prepared and prefiltered
(0.45
µm Millipore, Type HA) polyethylene glycol (MW
20,000, Sigma Chemical Co., St. Louis, MO)was
added to further coat and stabilize the
granules.
The protein-gold was concentrated and
separated from excess protein by centrifugation
in polycarbonate tubes at 8700 x g for 30 min.
The supernatant was discarded, and the
concentrated red pool resuspended to 1.0 ml in
sterile filtered (0.22 µm Millipore) protein-free
Tyrode's buffer, pH 7.3.
Protein Preparation
Humanfibrinogen (Sigma) was dissolved in
Tris-buffered saline (TBS, 0.01 M Tris, 0.15 M
NaCl}, pH 7.4. Contaminating fibronectin was
removed by passing the sample over an affinity
column of gelatin-agarose
(32). Aliquots of
relatively fibronectin-free
(s 0.5% protein by
weight as determined by fibronectin ELISAand
SOS-PAGE)fibrinogen of -1.0 mg/ml were frozen in
dry ice-isopropanol and stored at -70°C. Gels
showed that other protein contaminants (e.g.,
plasmin[ogen]) were not present in appreciable
amounts. Prior to use, samples were dialyzed
overnight against 0.005 M NaCl and centrifuged at
15,000 x g for 20 min. to remove aggregates.
The monoclonal antibody 10E5, which is
directed against the human platelet glycoprotein
llb/llla
complex (GP !lb/Illa)
(12), was a gift
of Dr. Barry Coller (State University of NewYork
at Stony Brook}. Samples of -1.0 mg/ml were
stored at 4°C.
Stock solutions of normal human lgG (Hu IgG,
5 mg/ml) and bovine serum albumin (BSA, 2-5
mg/ml) were prepared in deionized distilled water
and diluted to the desired concentration.
Both
proteins were purchased (Sigma) as lyophilized
powders, and were stored at 0°C after
reconstitution.

and Methods

Preparation of Colloidal Gold
A stock solution of colloidal gold granules
having an average diameter of 18-20 nm was
prepared by reducing HAuCl4with trisodium citrate
(14-18).
A 4% solution of HAuCl
4 (0.5 ml) was
added to 200 ml of deionized distilled water and
brought to a boil.
Freshly prepared 1% trisodium
citrate
(5.0 ml} was added rapidly to the boiling
mixture and refluxed for 30 min. A color change
from dark blue to red, indicative of the
formation of monodisperse colloidal particles,
occurs during heating.
The resulting colloidal
gold solution was stored at 4°C under sterile
conditions.
Prior to conjugation with protein,
the pH of the solution was adjusted for
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Platelet Preparation
Platelets were obtained from normal healthy
adult volunteers by antecubital venipuncture.
Blood samples were anticoagulated with either 10
mMEGTAor 0.38% trisodium citrate.
Plateletrich plasma (PRP) was prepared by centrifugation
of whole blood at 140 x g for 15 min. at room
temperature.
For aggregation studies, PRPwas
prepared by centrifuging citrated blood at 100 x
g for 10 min. in order to obtain a platelet count
high enough to allow the instrument to detect
platelet aggregation.
Platelets were separated
from plasma proteins by gel-filtration
on a
column of Sepharose CL-2B. The column was
equilibrated with calcium-free Tyrode's buffer,
pH 7.3 (136 mM NaCl, 2.7 mMKCl, 0.42 mMNaH2P04,
12 mMNaHC0
3 , 2 mMMgCl2 , 5 mMdextrose, and 2
g/l BSA). Gel-filtered platelets (GFP) were
collected in the void volume and were activated
either in suspension or on Formvar-coated nickel
Maxtaform grids (E.F. Fullman, Schenectady, NY).
Labelling the Fibrinogen Receptor
Drops of GFPwere allowed to surface
activate on Formvar-coated grids in a moist
chamber maintained at 37°C for -20 min. Filmed
grids containing adherent platelets were rinsed
in protein-free buffer after a majority of the
platelets were judged to be well-spread, as
observed by phase contrast microscopy. Surfaceactivated platelets were labelled by incubating
individual grids in 20 µl drops of the
appropriate gold conjugate (FGN/Au, 10E5/Au, Hu
IgG/Au, or BSA/Au)for 5 min. at room
temperature.
The grids were then thoroughly
washed in protein-free buffer and prepared for
electron microscopy.
GFP were activated in suspension by
incubation with 20 µMepinephrine bitartrate or
20 µMadenosine diphosphate (both from Sigma) for
5 min. at 37°C. Aliquots (100 µl) of the
activated platelet suspension were then incubated
with an equal volume of label, consisting of 50
µl gold-conjugated protein and 50 µl protein-free
buffer supplemented with CaCl2 to give a final
Ca+ con~intration (in suspension of activated
GFP + Ca -supplemented label) of 1 mM.
Activation/labelling
was stopped by addition of
10 ml of 1%glutaraldehyde in 0.1 M HEPES,pH
7.3. After a 30 min. fixation, platelets were
collected by filtration
on 0.4 µm pore size
polycarbonate membranes (13 mmdiameter
Nuclepore, Nuclepore Corporation, Pleasanton, CA)
and prepared for SEM.
Figure 1. Surface-activated platelets labelled
with 18 nm colloidal gold conjugated to human
fibrinogen (FGN/Au). Early in the spreading
process (A), very few FGN/Aulabels bind
(arrows). As activation continues and the
hyaloplasm of the platelets flattens (B), more
labels bind over the entire platelet surface,
including on the pseudopodia (arrows). As
spreading continues, the FGN/Aulabels begin to
clear from the outer edges of the platelet
surface (C) until they are completely centralized
in the plane of the membrane, as in this nearly
fully-spread form (D). Bar = 1 µm.
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Aggregation Studies
Aggregation was monitored in a Payton dual
channel aggregometer (Payton Scientific Inc.,
Buffalo, NY). GFP at ~152i000/µl were
supplemented with 1 mMCa (final concentration)
and 200 µg/ml human FGN, resulting in a final
platelet count of ~120,000/µl. The suspensions
of GFP (500 µl) were maintained at 37°C and
stirred at 1000 rpm with teflon-coated magnetic
stir bars in siliconized cuvettes.
Activating
agents were added in small volumes (1/100 volume
of GFP), and responses recorded on a dual channel
Payton Aggrecorder. Aggregation was stopped by
the addition of 10 ml of 1%glutaraldehyde in 0.1
M HEPES,pH 7.3.
Samples were fixed for 30 min.
at room temperature, collected on filters,
and
prepared for SEM.

R.M. Albrecht

A seemingly greater proportion of shapechanged platelets was observed in activated
suspensions (not shown) than was observed in
unactivated samples. Similarly-shaped platelets
from either ADP-or epinephrine-treated samples
demonstrate similar degrees of FGN/Aubinding
(Figures 28 and 2C). Relatively unchanged
platelets do not exhibit appreciable FGN/Au
labelling, as was the case with unactivated
suspensions.
Binding of FGN/Auoccurs primarily
on platelets with two or more pseudopodia,
whether the activating agent is 20 µM ADPor 20
µMepinephrine.
The FGN/Aulabelling observed in
all suspensions was also markedly less than that
observed on the more extensively shape-changed
surface-activated
platelets (compare Figures 2 AC with Figures lC and 10).
To test for the presence of the GP !Ib/l!Ia
fibrinogen receptor, the binding of goldconjugated anti-GP Ilb/llla
(10E5/Au) was
examined. In unactivated platelet suspensions
(Figure 3A), both round and pseudopodial
platelets demonstrate considerable binding of
10E5/Au. The labelling occurs over the entire
surface of the platelets,
including the
pseudopodia. Similarly, both round and
pseudopodial platelets in suspensions activated
with 20 µMepinephrine bound 10E5/Auovert e
entire platelet surface (Figure 38). No
difference in 10E5/Au labelling was noted between
control and epinephrine-activated
suspensions.
Neither surface-activated
platelets nor platelet
suspensions (unactivated, epinephrine-activated,
or ADP-activated) incubated with Hu IgG/Au or
BSA/Audemonstrated labelling.
The relationship of platelet shape change to
aggregation stimulated by ADPor epinephrine was
also examined. Suspen ions of GFP supplemented
2 were activated with 20
with fibrinogen and Ca+
µMADPor 20 µM epinephrine, and the course of
aggregation was followed. HEPES-buffered
glutaraldehyde was added after maximal
aggregation was achieved, and the samples were
processed for SEM. The resultant aggregation
curves are shown in Figure 4. ADPproduced more
rapid and more extensive aggregation than
epinephrine, as has been previously reported
(39,47,50).
The shape change of both aggregated and nonaggregated platelets from these samples is shown
in Figures 5 and 6. After treatment with 20 µM
ADP, all the platelets found in aggregates
possess multiple pseudopodia. In addition, a
large number of non-aggregated platelets are
shape-changed; however, any round or disco'd
platelets in the sample are found amongthe nonaggregated population rather than involved in
aggregates.
Similarly, after treatment with 20
µMepinephrine, all the aggregated platelets
display multiple pseudopodia, and round or
discoid platelets are found exclusively in :he
non-aggregated portion of the sample.

Scanning Electron Microscopy
All samples were fixed in 0.1 M HEPESbuffered 1%glutaraldehyde, pH 7.3, for 30 min.
at room temperature, and post-fixed in 0.05%
HEPES-buffered Oso4 for 15 min. Specimens were
dehydrated through a graded series of ethanol to
absolute ethanol, itself dried by storage over
molecular sieve. Samples were dried by the
critical point procedure in an apparatus equipped
with an in-line molecular sieve and a hydrophobic
water-excluding filter.
Samples were sputter
coated with ~10 nm gold-palladium (Auto
Conductavac, SeeVac, Inc., Pittsburgh, PA) and
viewed on a JEOLJSM-35Cscanning electron
microscope at 15 kV accelerating voltage.
Results
The binding pattern of FGN/Auto surfaceactivated human platelets is shown in Figures 1
A~D. Little or no labelling occurs on platelets
in relatively early stages of activation.
However, flattened pseudopodial platelets show
extensive binding of FGN/Auover the entire
surface, including out onto the pseudopodia. We
have previously shown that as platelet activation
and spreading continue, the FGN/Auclears from
the outer edges. Finally, in fully spread
platelets,
FGN/Aulabels are centralized in the
plane of the membrane. Correlative HVEM
analysis
demonstrates that the individual FGN/Aulabels
are localized exclusively over the inner
filamentous zone of the subjacent cytoskeleton
(23).
In contrast to the extensive labelling
observed on highly shape-changed, surfaceactivated platelets,
platelets labelled in
suspension show minimal binding of FGN/Au.
Figure 2A shows the labelling of unactivated
platelets incubated in suspension with FGN/Au.
The majority of platelets in these samples appear
to remain round or discoid, or display one short
spicule.
However, some platelets exhibit
pseudopodia, even in the absence of a stimulating
agent or surface. The FGN/Aulabelling observed
in unactivated suspensions appears to occur on
these shape-changed, pseudopodial platelets
rather than on those which are round or discoid,
or which have one spicule.

Discussion
The
round or
platelets
lib/Illa
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Figure 3. Platelets labelled in suspension with
18 nm colloidal gold conjugated to an antibody
directed against the GP !lb/Illa complex
(10E5/Au). As also shown in Figure 2A,
unactivated suspensions contain a few
pseudopodial platelets (3A). However, in
contrast to the labelling observed with FGN/Au,
10E5/Au (arrows) binds to both unactivated round
or discoid platelets (seen at the top right of
the field), and pseudopodial platelets.
Following activation with 20 µM epinephrine (3B),
the labelling pattern of 10E5/Au remains the
same; i.e., both unchanged and pseudopodial
platelets express the GP !lb/Illa fibrinogen
receptor.
Bar = 1 µm.

Figure 2. FGN/Aulabelling of platelets
activated in suspension and collected on
polycarbonate filter membranes. Even in
unstimulated suspensions (A), a few platelets
possess pseudopodia and bind FGN/Au(arrows),
whereas only an occasional label can be observed
on round and discoid platelets.
Following
stimulation with 20 µM ADP(B) or 20 µM
epinephrine (C), a higher proportion of platelets
are shape-changed (not shown), but binding of
FGN/Au(arrows) is still primarily limited to
pseudopodial platelets regardless of stimulating
agent. The holes in the background are pores of
the filter membrane. Bar = 1 µm.

surface regardless of platelet shape. Treatment
of platelet suspensions with epinephrine prior to
labelling does not alter the binding of 10E5/Au
to individual platelets as compared to that
observed in untreated samples. Thus, epinephrine
activation does not cause an increase in the
expression of the ·GP !lb/Illa fibrinogen receptor
on the platelet surface.
Binding of FGN/Auto unactivated or early
activation stage platelets in suspension is
sparse as compared to the FGN/Aulabelling seen
on highly shape-changed, late activation stage
surface-activated
platelets.
The binding which
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laboratory have demonstrated that FGN/Aubinds to
spreading, dendritic-shaped surface-activated
platelets,
then redistributes
in the plane o'. the
membrane as activation and shape change continue
to their final stages (4,23,24).
The "Rainforest
Hypothesis" (33) proposes that shape change must
precede fibrinogen binding to platelets because
the increase in membrane surface area during
spreading reduces "shading" or blocking of
glycoprotein receptors in the "unde~story" _by
glycoproteins in the "canopy. 11 By inc~easing the
distance between individual glycoprotein
receptors, the canopy" is in essence eliminated,
and the GP IIb/IIIa complex which was "shaded" or
blocked in unactivated platelets,
becomes
accessible to the large fibrinogen molecule.
Molecules which are smaller and/or more flexible
than fibrinogen (antibodies directed against the
GP IIb/IIIa complex, fragments of the gammachain
of fibrinogen) are able to bind to unactivated
platelets by going between glycoproteins of the
"canopy, and ther~fore do not require in~reased
surface area to gain access to receptors in the
"understory."
In addition to the increase in
surface area during shape change, the
polymerization of actin into microfilaments which
follows platelet activation supports the
development of pseudopodia around microfilament
bundles (9,19,26,37,55,57,58).
The conversion of
actin from the globular to filamentous form has
also been shown to result in the "tethering" of
GP IIb/IIIa to the cytoskeleton (25,41,46,49),
which may produce conformational changes in the
receptor complex necessary for fibrinogen binding
to occur.
In contrast to the current results, several
previous studies have suggested that epinephrine
can stimulate platelet aggregation, apparently
mediated by fibrinogen binding, without producing
shape change and a concomitant increase in
surface area or cytoskeletal reorganization.
These data have been taken as evidence against a
shape change requirement for platelet aggregation
or fibrinogen binding. O'Brien (40) followed
platelet shape change during aggregation by
assessing the amplitude of oscillations
produced
by a population of stirred platelets in a light
path. This did not provide extensive information
on the shape of individual platelets involved in
aggregates.
In addition, it has been shown that
such turbidometric measurements are insensitive
to the formation of pseudopodia (1,22,31) which
are an important indicator of platelet shape
change. White (54) examined individual
epinephrine-aggregated platelets by transmission
electron microscopy; however, the thin sections
required for the work may not have reflected the
overall shape of the platelets.
Small
pseudopodia present in sections above or below
the plane of the individual sections may not have
been readily detected, and the extent of
pseudopod formation may have been
underestimated.
Therefore, although these
previous studies have suggested that shape change
(development of pseudopodia) is not a requirement
for fibrinogen binding and platelet aggregation,
the issue is not entirely resolved.
The effects of cytochalasin B (CB) on
platelet shape, aggregability,
and fibrinogenbinding capacity have additionally been taken as
II

0

Figure 4. Aggregometer tracings of susp~nsions
of gel-filtered
platelets su~plemented with 200
µg/ml fibrinogen and 1 mMCa T• then activated
with 20 µMADP(A) and 20 µMepinephrine (B).
Time increases along the abscissa, while the
ordinate scale indicates increases in light
transmission.
Maximumdeflection was set with
the Tyrode's buffer in which the platelets were
suspended. Activating agents were added at the
arrows. Upward deflection of the curve at the
end of the plateau is due to the volume change
upon the addition of HEPES-buffered
glutaraldehyde to the cuvette.
does occur appears to be limited to those
platelets in which the development of pseudopodia
and an accompanying increase in surface area have
taken place. This is the case whether the
platelets are from an untreated population, or
whether they are activated with ADPor
epinephrine.
In contrast, 10E5/Au labels
unactivated and early activation stage platelets
in suspension very well; the density of 10E5/Au
labelling appears to be quite similar to that of
FGN/Auon late and final stage surface-activated
platelets.
Apparently, the fibrinogen receptor
is present at all stages of platelet activation,
but not available to FGN/Auuntil a certain
degree of activation has occurred.
SEManalysis of platelet suspensions fixed
at the point of maximumaggregation in response
to ADP(Figures 4A and 5) and epinephrine
(Figures 4B and 6) clearly demonstrates that only
shape-changed, pseudopodial platelets participate
in aggregation.
A high proportion of the nonaggregated platelets have also developed
pseudopodia in both the ADP-and epinephrineactivated suspensions.
However, any unchanged
round or discoid platelets in the samples are
found only among the non-aggregated population.
Our present study has demonstrated that the
shape of platelets which are able to participate
in aggregation parallels that of platelets which
are able to bind FGN/Au. One can infer that the
binding of fibrinogen and aggregation are related
and are both preceded by shape change, regardless
of stimulus.
Previous results from our
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Figure 6. Platelets from the epinephrineaggregated sample illustrated
in Figure 48. As
observed in the ADP-activated samples, platelets
involved in aggregates following epinephrine
stimulation (A) are also exclusively those which
are pseudopodial.
A somewhat smaller proportion
of the non-aggregated platelets in the sample
demonstrate shape change. However, as with the
ADP-treated sample, round and discoid platelets
(arrows) are found only among the non-aggregated
population rather than participating
in
aggregates.
Bar= 1 µm.

Figure 5. Platelets from the ADP-aggregated
sample illustrated
in Figure 4A. Platelets
involved in aggregates (A) all exhibit
pseudopodia. Although most of the non-aggregated
platelets
(8) also demonstrate shape change, any
round or discoid platelets (arrow) found in the
sample are found in the non-aggregated portion
rather than participating
in aggregates.
Bar =
1 µm.
evidence that shape change is not required for
aggregation or fibrinogen binding. It has been
reported that CB-treated platelets seemingly
remain discoid when aggregated by either
epinephrine or ADP(54). A later study also
suggested that pretreatment with CB allowed
discoid platelets to aggregate in response to
ADP; in addition, the amount of fibrinogen bound
to CB-treated, ADP-stimulated platelets was not
significantly
different than the amount bound to
platelets
incubated with the CB vehicle (ethanol)
rather than CB (43). The reasons for the
increased aggregability of the non-shape-changed
platelets is not clear.
It is possible that CB
may have directly or indirectly influenced the
orientation or distribution
of GP !Ib/llla in the
platelet membrane. However, it should be noted

that, as in the case of the epinephrine studies,
platelet shape was evaluated by the techniques of
thin sectioning and turbidometric assessment of
the swirling pattern of the platelet suspension,
respectively.
As discussed above, these methods
may not be particularly
sensitive to pseudopod
formation.
Therefore, both the aggregation and
fibrinogen binding observed in these studies
could have been due to undetected shape-changed
platelets.
Additional work is necessary to
clarify this possibility.
In support of the idea of a shape change
(development of pseudopodia) requirement for
platelet aggregation, Milton and Frojmovic (30)
have reported that shape-changed platelets are
preferentially
recruited into aggregates
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following stimulation with either ADPor
epinephrine.
Their conclusions regarding the
shape of aggregated platelets were based
primarily on evidence derived from assessing the
shape of non-aggregated platelets at various
times throughout aggregation.
Their use of light
microscopy (including phase contrast, darkfield,
and differential-interference
contrast) did not
permit detailed observation of individual
platelets in aggregates.
Therefore, in the
current study, we have employed SEManalysis of
platelet shape change in response to ADPand
epinephrine stimulation to provide additional
evidence concerning the shape of activated and
aggregated platelets,
and also to explore the
role of fibrinogen binding in platelet
aggregation.
Although an ADPscavenger such as apyrase
was not used in the epinephrine-activated
samples
shown here, we believe the shape change
illustrated
is an effect of epinephrine and is
not due to ADPsecreted from dense granules.
In
preliminary studies, we have observed that
stirred suspensions which are fixed at very early
time points (30 sec. or less) following exposure
to epinephrine contain small (4-5 platelets)
aggregates of pseudopodial platelets (not
shown). The effects of ADPin epinephrinetreated suspensions are thought to be more
apparent on the much larger aggregates associated
with the second wave of aggregation (52). SEM
analysis of epinephrine-aggregated GFP in the
presence of an ADPscavenger and/or utilization
of lumiaggregometry (simultaneous measurement of
aggregation and secretion by means of the
luciferin-luciferase
system) in conjunction with
SEMwill be required in order to address this
important issue. In addition, localization of
fibrinogen on aggregated platelets,
as well as
investigation of the temporal relationship
between fibrinogen binding and platelet
aggregation, is warranted in order to more
clearly elucidate the mechanism(s) underlying
platelet-platelet
interactions.
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Discussion with Reviewers
M.B. Zucker: The general view is that
circulating platelets are discoidal; perhaps a
few have one or two pseudopods projecting from
the rim of the disc. On activation, the
platelets assume a more spherical configuration
(though they do not have a smooth surface) and
they develop more pseudopods. The platelets
described here as "round" are almost certainly
discs that have settled onto the surface. Do you
feel that SEMis a good technique for
illustrating
the thickening of the discs that
constitutes part of the shape change? Also,
aggregates formed by epinephrine in warmed,
aspirin-treated
platelet-rich
plasma consist
largely of discs when viewed by phase contrast
microscopy. As you point out in the Discussion,
the platelets used in this experiment have
doubtless been exposed to platelet-derived
ADP.
Do you feel they are suitable for studying the
shape change caused by epinephrine?
Authors: We feel that our technique of
studying epinephrine-induced shape change through
the use of SEMis superior to the use of phase
contrast microscopy. The "halo" surrounding the
cell or platelet in question which occurs in
phase contrast microscopy obscures the detection
of small pseudopodia which may be present.
This
is because the modulation transfer function for
phase contrast microscopy is minimal for objects
in the size range of small pseudopodia. On the
other hand, the modulation transfer function is
nearly half maximal when these objects are viewed
by differential
interference contrast (DIC)
microscopy. Additionally, video enhancement can
be applied to boost the range of contrast
obtainable when viewing objects of this size by
DIC microscopy. In our own work (unpublished),
we have found that warmed, aspirin-treated
platelets which are activated with 20 µM
epinephrine for 5 minutes and then fixed in 1%
glutaraldehyde do not appear to possess
pseudopodia when viewed by phase contrast
microscopy. However, platelets taken from this
same sample are observed to possess multiple
pseudopodia when viewed by video-enhanced DIC
microscopy. Therefore, we do not feel that phase
contrast microscopy is the best method for
assessing the platelet shape change response.
With regard to the discoid (as opposed to
spherical) appearance of epinephrine-treated
platelets,
we believe that the important aspect
of the response is not the thickening of the
discs, but the development of pseudopodia: This
can be determined by the use of stereo pairs of
scanning electon micrographs (Figure 7) which
provide a three-dimensional view of the sample.
The platelets in this stereo pair are from the
same sample as seen in Figure 2C. FGN/Aulabels
are clearly seen to select not for round over
discoid platelets,
but for platelets which have
developed pseudopodia as opposed to those which
have not.
J.F. Mustard: Epinephrine does not
aggregate platelets in the presence of
physiological concentrations of calcium when
traces of other agonists such as ADPare
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Figure 7. Stereo
pair of platelets
from the same
sample as in
Figure 2C. See
text for
description.
Bar = 1 µm.

M.M. Frojmovic: Howdo you know that an
accompanying change in surface area has taken
place with shape change? This is expected (see
M.M. Frojmovic and J.G. Milton, Physiological
Reviews, 62:185-261, 1982), especially for ADPactivatedplatelets,
but more quantitative
studies are generally required in this area.
Authors: Our claim that an increase in
surface area accompanies the development of
pseudopodia is based on two pieces of evidence.
First, although we have not made direct
.
morphometric measurements, the apparent size of
the main body of the platelet does not decrease
when pseudopodia begin to appear, as would be
expected if the ratio of surface area to internal
area did not increase.
Second, surface area
comparisons between unactivated and fully spread,
surface-activated
platelets have been calculated
(see reference 32), and have shown that the
surface area approximately doubles during the
surface activation process.
It is more likely
that this two-fold increase occurs throughout
surface activation as a continuum, much the same
as the shape change process itself proceeds on a
continuum, from round or discoid, to
pseudopodial, spreading pseudopodial, spreading,
and finally, to the fully spread shapes (see
Figure 1). We agree, however, that further
morphometric evaluation of this issue is
required.
J.M. Gerrard: It would appear that the
critical
test of the Rainforest Hypothesis
involves labelling and tagging other
glycoproteins (e.g., glycoprotein lb) and then .
looking at the distance between such glycoprote,n
molecules in the unactivated and activated
discoid and shape-changed platelets to see if
indeed there is a relative increased distance
between these glycoprotein molecules in the areas
where glycoprotein IIb/IIIa fibrinogen binding
receptor becomes available.
Have you done such
studies with antibodies that would label
glycoproteins which might act as a "canopy" or
covering?

unavailable.
In our own work, studies that have
been carried out in platelets in a low calcium
medium led to an activation of the arachidonate
pathway that produces aggregation which is not
due to the primary stimulus, but due to the
secondary effect of aggregation on the
arachidonate pathway. This can be blocked by
treatment of the cyclo-oxygenase with a nonsteroidal anti-inflammatory drug or by making
certain that the platelets are suspended in the
presence of physiological concentrations of
calcium and that there are no traces of other
agonists such as ADPin the suspending medium.
Do you feel that a likely explanation for your
observed epinephrine effect is that, in a medium
with low calcium, the epinephrine induced the
platelets to stick transiently to each other as
discs, which then led to activation of the
arachidonate pathway which produced shape change
in the larger aggregates {Figures 5 and 6)?
Authors: There are reports in the
literature
of platelets exhibiting a primary
aggregation response to epinephrine after ..
treatment with aspirin (J.S. Bennett, G. V1la1re,
J.W. Burch, J Clin Invest, 68:981-987, 1981) and
after treatment with aspirin and subsequent
incubation with either apyrase or creatine
phosphate/creatine
phosphokinase. (E.I.
Peerschke, Blood, 60:71-77, 1982). Although both
arachidonate metabolites and secreted ADPmay
have played a role in the shape change observed
in the large aggregates, we have noted similar
shape change in the small, initial aggregates
associated with primary aggregation.
Since all
platelet suspensions were supplemented with a
physiological concentration of calcium ions, we
do not feel we have stimulated the arachidonate
pathway outside of the primary epinephrine
stimulus.
Therefore, we maintain the point that
the shape of aggregated platelets {Figures 5A and
6A) parallels that of platelets which are able to
bind FGN/Au.
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Authors: Actual measurement of the distance
between labelled glycoprotein molecules would be
difficult
using the system described here because
of the somewhat limited resolving power of
traditional
SEM. However, the recent
availability
of a low voltage, ultrahigh
resolution (objects in the 10-20 A range can be
resolved) SEMwould make such experiments
feasible.
It is also possible that binding of
gold-conjugated native ligands will shed
additional light on the proposed Rainforest
Hypothesis. For instance, if glycoprotein Ibis
a member of the "canopy," incubation with its
native ligand, van Willebrand factor, may
partially block subsequent binding of fibrinogen
to GP IIb/IIIa,
which we propose to be a member
of the understory.
On the other hand, incubation
with fibrinogen should have little effect on the
subsequent binding of van Willebrand factor if
the model holds true.
M.B. Zucker: Your observation that much
more 10E5/Au than FGN/Aubinds to each activated
platelet is not consistent with the results with
iodine-labelled
material, which indicate about
the same number of binding sites on activated
platelets.
Do you have any explanation for this?
Authors: On fully spread, surface-activated
platelets,
we observe nearly equal numbers of
FGN/Auand 10E5/Au labels.
During the activation
process, labelling with FGN/Auappears to be less
dense than that seen with 10E5/Au, which labels
GP IIb/I!Ia very well, even on unactivated
platelets.
We feel that the absence of FGN/Au
labelling observed on unactivated platelets,
and
the apparently decreased labelling of FGN/Auas
compared to 10E5/Au on platelets activated in
suspension, is due to steric hindrance occurring
at the level of the protein molecule rather than
at the level of the colloidal gold bead.
However, the use of a more concentrated colloidal
suspension of smaller beads for a longer period
of time may more accurately depict the true
situation,
and permit earlier, more rapid binding
of FGN/Auto receptors as they become available
for fibrinogen binding.
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